Summary by Moomoo AI
Sanofi announced that its two-valent RSV candidate vaccine, SCB-1019, developed by Clover Biopharmaceuticals, obtained positive preliminary immunogenicity and safety data in Phase I clinical trials in the elderly population (age 60-85). The trial took place in Australia, and 48 elderly participants received SCB-1019 or saline placebo. The results showed that on the 28th day after vaccination, the geometric mean titers (GMT) of neutralizing antibodies against RSV-A and RSV-B were as high as 7,906 IU/mL and 46,674 IU/mL, respectively, significantly higher than the placebo group. In addition, SCB-1019 was well-tolerated and no serious adverse events were observed. These data support Clover's strategy for developing a two-valent RSV-A/B PreF vaccine, which may have differential advantages in safety and reactogenicity. Complete safety and immunogenicity results are expected to be announced by the end of 2024 to support further development of SCB-1019.